Immuneactivation in neurodegenerative diseases

Not Applicable

• Conditions: F00; F03; Dementia in Alzheimer disease; Unspecified dementia

• Registration Number: DRKS00007914
• Lead Sponsor: andesnervenklinik Wagner-Jauregg

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2006-12-31
• Study Start: 2015-03-25
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

Patients:
Criteria for Alzheimers disease (NINDS ADRDA) and mild cognitive impairment (Petersen et al).

controls:
age above 18, healthy controls

Exclusion Criteria

for all:
Psychiatric diseases (other then dementia)
metabolic diseases
Neurodegenerative diseases other then dementia
Vitaminsupplementation for the last 6 weeks

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Explorative study. <br><br>primary outcomes:<br>levels of immuneactivation between subgroups at baseline and after three months<br><br>(determination as described in pubished trials)<br><br>

Secondary Outcome Measures

Name	Time	Method
Correlation between clinical parameters (mini mental status examination) and laboratory markers (neopterin, folic acid, malondialdehyde, kynureine, vitamin b12, tryptophan, carbonyl proteins) at baseline and after three months of supplementation